Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,297
Out of 4,989 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $30.25 | +38.84% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $128.18 | +192.56% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $68.35 | +68.25% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $75.00 | +22.67% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $17.67 | -32.09% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.07 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $41.66 | +116.03% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $245.99 | +9.76% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $82.79 | -17.86% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.10 | +271.90% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $123.29 | +123.05% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $26.75 | +38.32% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $67.50 | -11.11% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $98.06 | -64.31% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $326.97 | -75.23% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $30.25
Upside: +38.84%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $128.18
Upside: +192.56%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $68.35
Upside: +68.25%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $75.00
Upside: +22.67%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $17.67
Upside: -32.09%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.07
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $41.66
Upside: +116.03%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $245.99
Upside: +9.76%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $82.79
Upside: -17.86%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.10
Upside: +271.90%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $123.29
Upside: +123.05%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $26.75
Upside: +38.32%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $67.50
Upside: -11.11%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $98.06
Upside: -64.31%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $326.97
Upside: -75.23%